Exploring differential prescribing between anti-epileptic drugs in epilepsy patients with a history of mood disorders

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 3, 2010, Pages 289-295

  Ishihara Paul, Lianna ^a   Webb, David J ^a   Irizarry, Michael ^a   Weil, John ^a  

^a NONE

Author keywords

Anti convulsant; Bipolar; Channeling bias; Depression; Epilepsy

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ANAMNESIS; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DATA BASE; DEPRESSION; DRUG COMBINATION; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTICONVULSANTS; BIPOLAR DISORDER; DATABASES, FACTUAL; DEPRESSION; EPILEPSY; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77649226950     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1905     Document Type: Article

References (20)

1. Freemantle N, Irs A. Observational evidence for determining drug safety. Br Med J 2008; 336(7645): 627-628. 10.1136/bmj.39491.493252.80.
2. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991; 10(4): 577-581. 10.1002/sim.4780100409.
3. Collet J, Boivin J. Bias and confounding in pharmacoepidemiology. In Pharmacoepidemiology (3rd edn), Strom BL (ed.). John Wiley: Chichester, 1998; 775-784.
4. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1): 41-55. 10.1093/biomet/70.1.41.
5. Shneker BF, Cios JS, Elliott JO. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009; 72(11): 987-991. 10.1212/01.wnl.0000344403.13815.8d.
6. Bell GS, Mula M, Sander JW. Suicidality in people taking antiepileptic drugs: What is the evidence? CNS Drugs 2009; 23(4): 281-292.
7. Hesdorffer DC, Kanner AM. The FDA alert on suicidality and anti-epileptic drugs: Fire or false alarm? Epilepsia 2009; 50(5): 978-986.
8. Post RM. Differing psychotropic profiles of the anticonvulsants in bipolar and other psychiatric disorders. Clin Neurosci Res 2004; 4(1-2): 9-30. 10.1016/j.cnr.2004.06.003.
9. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003; 158(9): 915-920. 10.1093/aje/kwg231.
10. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48(1): 62-68.
11. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4): 392-400.
12. Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006; 20(3): 219-231.
13. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58(9): 844-850.
14. Achte K. Depression and suicide. Psychopathology 1986; 19 (Suppl 2): 210-214.
15. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302(6779): 766-768.
16. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45(5): 419-425. 10.1046/j.1365-2125. 1998.00701.x.
17. Bowden CL. Use of anticonvulsants and bipolar disorder (too much or too little?). Program and Abstracts of the 5th International Conference on Bipolar Disorder. Interactive Sessions: Ask the Experts [June 12-14, 2003], 2003. Pittsburgh, Pennsylvania.
18. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62(8): 1252-1260.
19. Chen H, Deshpande AD, Jiang R, Martin BC. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf 2005; 14(9): 629-638. 10.1002/pds.1051.
20. Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed medicaid population. J Manag Care Pharm 2002; 8(4): 266-271